CLASS ACTION NOTICE: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, with a deadline for potential lead plaintiff representatives set for January 16, 2026 [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success likelihood [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].